CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
InSphero has launched a 14-Day Hepatotoxicity Testing Service designed to meet increased demand for contract screening in its patent-pending 3D InSight Human Liver Microtissues. The service streamlines toxicity testing of compounds in InSphero’s 3-D liver microtissues by initiating regular screening runs on the first Tuesday of each month, at $990 per compound.
The service takes advantage of the more liver-like functionality and greater than four-week in vitro lifespan of primary liver cells (hepatocytes and Kupffer cells) when co-cultured as 3-D spheroids, allowing repeated dosing of compounds over the two-week testing protocol. The service quantifies total cellular adenosine triphosphate as a measurement of cell viability, an assay routinely used to assess drug-induced liver injury. Results for test compounds and defined control compounds are returned to the customer three weeks after initial dosing.
InSphero, 800-779-7558